Neuphoria Therapeutics Inc.
Neuphoria Therapeutics Inc. (NEUP) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
neup · stock forecast · 2 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 2 Wall Street analysts in the past 3 months
Buy
2 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$7.00
Consensus
$7.00
+49.9% upside
Low
$7.00
Median: $7 · Last Close: $4.67
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $4.50 | ↓ 3.56% |
1-day model range: $4.43–$4.57. Peak: $4.57 (-3.56%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · NEUP · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-15 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2025-12-05 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-09-11 | Maxim Group | Maintains | Buy→Buy |
| 2025-08-26 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-02-04 | HC Wainwright & Co. | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Neuphoria Therapeutics Inc. (NEUP) stock. Of the recent 5 rating actions, 0 were upgrades and 1 were downgrades. 2 analysts currently cover NEUP.
Analyst Recommendation Trends
NEUP analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$12M
↓ 79.4% YoY
Revenue Next Year
$9M
↓ 25.0% YoY
EPS This Year
$-4.07
EPS Next Year
$-2.43
↓ 40.3% YoY
EPS ForecastReported vs Estimated
Analysts forecast NEUP EPS of $-4.07 for the current fiscal year, based on estimates from 1 analysts. The NEUP revenue forecast is $12M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The NEUP stock forecast is supported by two independent data sources: analyst consensus ratings from 2 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus NEUP price target is $7.00 (+49.9% upside), with an analyst consensus of Buy.
The NEUP short-term stock prediction for tomorrow is $4.50 (-3.56%).
Neuphoria Therapeutics Inc. trades on NASDAQ under the ticker NEUP. The NEUP stock outlook for 2027 is broadly positive, supported by a Buy consensus among 50% of covering analysts.
Frequently asked questions
NEUP forecast · 8 questionsAccording to 2 Wall Street analysts, the average 12-month NEUP price target is $7.00, with a high forecast of $7.00 and a low of $7.00. The median price target is shown in the chart above when available. This implies +49.9% potential upside from the current price of $4.67.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.